Study overview
Tusa et al. conducted a cohort study using FinnGen Data Freeze 12, which integrates germline genetic data with Finnish national health registries for 402,739 individuals. Among these, 21,609 received a glaucoma diagnosis after age 40 and formed the analytic cohort. Fourteen published glaucoma PRSs from the Polygenic Score Catalog were benchmarked using Cox proportional hazards models, and the best-performing PRS—developed by Truong et al. (PGS004765)—was selected for downstream analyses.1 The investigators then assessed lifetime glaucoma risk by age 85, evaluated the independent and combined contributions of PRS and family history, and examined 20-year cumulative incidences of IOP-lowering medication escalation, laser therapy, and incisional surgery.1
- Study topic: Polygenic risk score for lifetime glaucoma risk stratification and prognosis
- Journal and publication date: Ophthalmology, November 2026 (Vol. 133, No. 11)
- Study design: Cohort study; FinnGen biobank registry data
- Population: 402,739 Finnish adults; 21,609 with glaucoma diagnosed after age 40
- Exposure: Best-performing glaucoma PRS (Truong et al., PGS004765), benchmarked against 13 other published PRSs
- Primary outcomes: Lifetime glaucoma risk by age 85; 20-year cumulative incidence of medication escalation, laser therapy, and incisional surgery
- Key result: Highest PRS tier (≥99th percentile) associated with 45.3% lifetime risk; high-PRS decile had 60.6% vs. 38.4% cumulative incidence of medication escalation vs. lowest decile over 20 years
- Major limitation: Cohort limited to Finnish (European) individuals; findings may not generalize to other ancestries
Key findings
The best-performing PRS demonstrated a hazard ratio (HR) of 3.32 (95% CI, 3.21–3.43) for glaucoma in individuals at or above the 90th PRS percentile compared with the average-risk reference group (20th–80th percentile).1 Lifetime glaucoma risk by age 85 ranged substantially across PRS categories: 2.5% (95% CI, 1.7%–3.3%) among those in the lowest percentile, rising to 31.9% (95% CI, 30.5%–33.3%) in the 95th to 99th percentiles and 45.3% (95% CI, 42.3%–48.1%) in the 99th percentile or higher.1
PRS and first-degree family history contributed independently to glaucoma risk. When family history was added to a high-PRS model, the PRS effect size decreased by only 4.2%, indicating that the two factors largely capture distinct aspects of genetic susceptibility.1 Model discrimination, assessed by the concordance index (C-index), improved from 0.60 at baseline to 0.71 with PRS alone and 0.72 when PRS and family history were combined.1
Prognosis also tracked with PRS tier over the 20-year follow-up. Cumulative incidences of IOP-lowering medication escalation (60.6% vs. 38.4%), laser therapies (39.8% vs. 22.9%), and incisional surgeries (15.8% vs. 9.5%) were higher in the highest PRS decile compared with the lowest.1 Glaucoma-related health care costs were 1.6-fold greater in the highest PRS decile (median €2,960) versus the lowest (median €1,849).1
Clinical context
Screening for glaucoma in the general population has historically offered limited yield, in part because of the disease's asymptomatic nature and low overall prevalence.2 Risk stratification tools capable of identifying individuals at substantially elevated lifetime risk could help concentrate screening resources and intensify follow-up after diagnosis. The PRS evaluated in this study incorporates more than 1 million genetic variants, and the authors note that PRSs incorporating larger numbers of variants generally performed better than those with fewer.1
Interpretation
Tusa et al. concluded that PRS-guided stratification could inform both population-level screening strategies and the intensity of post-diagnosis management.1 The authors also note that an individual's PRS captures genetic susceptibility not fully reflected in family history, and that the combination of both measures provides the most complete risk picture.1 The study extends prior work by linking elevated PRS not only to diagnosis but also to measurable prognostic outcomes across two decades of follow-up.1
Limitations
The cohort comprised exclusively Finnish (European) individuals, and the authors caution that generalizability to other ancestral populations may be limited, as polygenic risk scores typically show reduced predictive accuracy in populations that differ from their training samples.1 Detailed clinical parameters—including IOP measurements, vertical cup-to-disc ratios, optic nerve imaging, and visual field data—were not available in the registries and could not be incorporated into disease severity analyses.1 The investigators also note that available IOP-lowering therapies and laser treatment guidelines evolved over the follow-up period, which may affect the generalizability of the prognosis findings.1
Future research
The authors call for randomized prospective studies to evaluate optimal integration of PRS into clinical screening protocols and to assess cost-effectiveness.1 Ongoing trials—including EyeLife in the Netherlands, the Genetic Risk Assessment of Degenerative Eye Disease (GRADE) in Australia, and a screening study at Mount Sinai Biome and Mass General Brigham—are expected to provide prospective evidence on PRS utility in glaucoma detection.1 The investigators also note that developing PRSs with greater applicability across diverse ancestries will be essential for broader clinical implementation.1
References
1. Tusa ES, Tamlander M, Ripatti S, et al. Polygenic risk impacts lifetime risk and prognosis of glaucoma. Ophthalmology. 2026;133(11):1308-1317. doi:10.1016/j.ophtha.2026.06.003
2. Chou R, Selph S, Blazina I, et al. Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;327(20):1998-2012. doi:10.1001/jama.2022.6290